{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(1)"],"submitter":["Yang MH"],"pubmed_abstract":["<h4>Background</h4>In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.<h4>Methods</h4>This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was "],"journal":["BMC cancer"],"pagination":["1227"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11452986"],"repository":["biostudies-literature"],"pubmed_title":["Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen."],"pmcid":["PMC11452986"],"pubmed_authors":["Chang YF","Lin JC","Wang HM","Chen JP","Yen CJ","Lu WC","Lou PJ","Hua CH","Chien CY","Yiu CY","Lien MY","Lin CL","Yang MH","Hsieh JC","Wu SY","Hsieh MC","Wang HC","Huang TL","Chu PY","Wang CC","Chen TH","Lu HJ","Huang HC","Liu YC"],"additional_accession":[]},"is_claimable":false,"name":"Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen.","description":"<h4>Background</h4>In recent years, the addition of cetuximab to chemotherapy has improved treatment outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). In this study, we present the real-world survival data of R/M HNSCC patients who received cetuximab-containing regimens from thirteen medical centers in Taiwan, as well as a three-level risk stratification model for this patient population.<h4>Methods</h4>This study enrolled R/M HNSCC patients from thirteen medical centers in Taiwan who received cetuximab-containing regimens from January 1, 2017 to June 6, 2022. The cases were divided into a training cohort and a validation cohort based on the start of treatment. Overall survival (OS) was evaluated in both cohorts and exploratory analysis was ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-07T08:06:52.292Z","creation":"2025-04-04T02:05:05.92Z"},"accession":"S-EPMC11452986","cross_references":{"pubmed":["39369189"],"doi":["10.1186/s12885-024-12425-0"]}}